Arcus Biosciences Completes Stock Offering, Raises Approximately $141.6 Million
Arcus Biosciences, Inc. (NYSE: RCUS) announced on February 18, 2025, that it has entered into an underwriting agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC for the offering, issuance ...
What is Wedbush’s Estimate for RCUS FY2029 Earnings?
Research analysts at Wedbush issued their FY2029 EPS estimates for shares of Arcus Biosciences in a note issued to investors ...
GlobalData on MSN2d
Precision reports initial outcomes from Hepatitis B trial of PBGENE-HBV
The trial was tailored to evaluate the therapy at multiple ascending dose levels, with three dose administrations per level.
These Analysts Just Made A Decent Downgrade To Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Forecasts
One thing we could say about the analysts on Arcus Biosciences, Inc. (NYSE:RCUS) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the ...
BioSpace3d
Gilead Passes on Option for Arcus’ Cancer Drug Despite Strong Early Data
The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...
Arcus Biosciences price target lowered to $17 from $22 at BofA
BofA lowered the firm’s price target on Arcus Biosciences (RCUS) to $17 from $22 and keeps a Neutral rating on the shares following Gilead’s ...
2RCUS : Arcus Biosciences Shares Are Down Today: What's Going On?
Arcus Biosciences Inc. (NYSE: RCUS) shares are trading lower Tuesday after the company announced a $150 million common stock ...
Gilead opts out of deal for Arcus cancer therapy
Arcus Biosciences (RCUS) stock falls as Gilead (GILD) decides not to buy rights to its anticancer drug casdatifan. Read more here.
The American Journal of Managed Care4d
Phase 1 Study Identifies Casdatifan Dose With Promising Responses in Pretreated Clear Cell RCC
Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory ...